Oleuropein

Oleuropein is the primary phenolic secoiridoid found in olive leaves and unprocessed olives, responsible for most of the cardiovascular and metabolic effects associated with olive-derived supplements. It exerts its effects largely through activation of AMPK signaling, inhibition of ACE activity, and upregulation of eNOS-mediated nitric oxide production.

Origin & History

Oleuropein is a secoiridoid glycoside primarily extracted from olive tree (Olea europaea L.) leaves, where it serves as a natural defense compound against herbivores and pathogens. Commercial extraction methods include solvent extraction with 80% ethanol (yielding ~13 mg/g dry leaf), microwave-assisted extraction, and purification via column chromatography achieving 95-98% purity.

Historical & Cultural Context

Olive leaves have been used in Mediterranean traditional medicine since Hippocrates (~400 BCE) as infusions for fevers, hypertension, and diabetes. The Greek physician Dioscorides (1st century CE) prescribed leaf decoctions for venomous bites and cardiac issues, with these practices persisting through Islamic medicine and European folk remedies for malaria-like fevers.

Health Benefits

• Reduces blood pressure: Meta-analysis of 12 RCTs (n=810) showed systolic BP reduction of -3.86 mmHg (moderate evidence quality)
• Improves glucose metabolism: RCT in 20 overweight men showed 15% reduction in postprandial glucose AUC with 20 mg/day (moderate evidence)
• Enhances insulin sensitivity: Clinical trial demonstrated improved QUICKI index (p=0.014) after 12 weeks supplementation
• Provides antioxidant protection: Inhibits LDL oxidation by 50% in vitro via Nrf2 upregulation pathway
• Anti-inflammatory effects: Modulates NF-κB pathway, reducing TNF-α and IL-6 (preliminary evidence from mechanistic studies)

How It Works

Oleuropein inhibits angiotensin-converting enzyme (ACE) and activates endothelial nitric oxide synthase (eNOS), increasing vascular nitric oxide bioavailability and reducing systemic vascular resistance. It also activates AMP-activated protein kinase (AMPK) in skeletal muscle and hepatic tissue, enhancing GLUT4 translocation and glucose uptake independent of insulin signaling. Additionally, oleuropein and its metabolite hydroxytyrosol suppress NF-κB-mediated inflammatory cytokine expression, contributing to improved insulin receptor sensitivity.

Scientific Research

Clinical evidence primarily comes from olive leaf extract (OLE) standardized to oleuropein content. A key RCT (PMID: 24015942) in 60 adults showed 500 mg OLE twice daily reduced systolic BP by 11.5 mmHg after 8 weeks. A meta-analysis (PMID: 32688483) of 12 RCTs confirmed significant reductions in both BP and HbA1c, though no large trials on isolated oleuropein exist.

Clinical Summary

A meta-analysis of 12 randomized controlled trials (n=810) demonstrated that olive leaf extract standardized for oleuropein reduced systolic blood pressure by a mean of 3.86 mmHg, with evidence quality rated as moderate. A small RCT in 20 overweight men found that 20 mg/day of oleuropein reduced postprandial glucose area under the curve by approximately 15%, suggesting meaningful improvements in glucose metabolism. Evidence for insulin sensitization comes from both human trials and mechanistic in vitro and animal studies, though large-scale RCTs specifically isolating oleuropein's insulin-sensitizing effects remain limited. Overall, the evidence base is promising but constrained by small sample sizes and variability in extract standardization across studies.

Nutritional Profile

Oleuropein is a secoiridoid polyphenol (phenolic glycoside) rather than a macronutrient-containing food ingredient; it does not contribute meaningful calories, protein, fat, or carbohydrates at typical supplemental doses. Key compositional data: Pure oleuropein (MW 540.5 g/mol) is the primary bioactive; typical olive leaf extract standardized preparations contain 15–40% oleuropein by dry weight. Related co-occurring bioactives in olive leaf extract include hydroxytyrosol (0.5–5% of extract), tyrosol, elenolic acid, oleoside, verbascoside (acteoside), luteolin-7-glucoside (~0.1–0.5%), apigenin-7-glucoside, and rutin. Olive oil contains oleuropein at lower concentrations (trace–0.1 mg/g) compared to olive leaf (up to 60–90 mg/g dry leaf) and unprocessed green olives (10–30 mg/g fresh weight). Supplemental doses studied clinically range from 20–1000 mg/day of standardized extract (equating to ~6–400 mg oleuropein). Bioavailability: Oral bioavailability is moderate; oleuropein undergoes extensive intestinal and hepatic hydrolysis to hydroxytyrosol (the primary circulating metabolite), elenolic acid, and oleuropein aglycone. Peak plasma hydroxytyrosol appears ~1–2 hours post-ingestion. Gut microbiota plays a significant role in conversion; bioavailability estimates for hydroxytyrosol equivalents range from 55–75% of ingested dose. Food matrix effects: co-ingestion with fat mildly enhances absorption. No relevant vitamin, mineral, or dietary fiber content at supplemental doses.

Preparation & Dosage

For hypertension: 500-1,000 mg olive leaf extract daily (providing 100-200 mg oleuropein) in divided doses. For blood glucose support: 20-50 mg oleuropein daily, typically from 250-500 mg of 20% standardized extract. General antioxidant support: 100-500 mg oleuropein equivalents daily from standardized extracts. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Hydroxytyrosol, Coenzyme Q10, Magnesium, Quercetin, Resveratrol

Safety & Interactions

Oleuropein is generally well tolerated at doses used in research (20–500 mg/day), with the most commonly reported side effect being mild gastrointestinal discomfort, particularly at higher doses. Due to its ACE-inhibiting and vasodilatory properties, oleuropein may potentiate the effects of antihypertensive medications, increasing the risk of hypotension, and caution is warranted when combining it with ACEi or ARB drug classes. Its blood-glucose-lowering activity also raises a theoretical interaction risk with insulin and oral hypoglycemic agents such as metformin or sulfonylureas. Safety data in pregnant or breastfeeding women are insufficient to establish a clear risk profile, and use during pregnancy should be avoided without medical supervision.